GlassScriptPhysician profile
Thomas H Black
NPI 1851474167
$4,867.34
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,286 · 2020: $1,274 · 2021: $1,408 · 2022: $885 · 2024: $14.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $967.46 | 2019-2022 | |
| Novo Nordisk INC | $569.26 | 2019-2022 | |
| Abbvie INC. | $490.29 | 2021-2024 | |
| Lilly USA, LLC | $489.85 | 2019-2022 | |
| Glaxosmithkline, LLC. | $387.07 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $251.42 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $185.59 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $141.51 | 2019 | |
| Grifols USA, LLC | $139.97 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $111.63 | 2020-2021 | |
| Astellas Pharma US INC | $108.75 | 2020-2022 | |
| Amarin Pharma, INC. | $98.86 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $77.11 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $76.17 | 2022 | |
| Eisai INC. | $68.56 | 2020-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.21 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.61 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $55.93 | 2020-2022 | |
| Antares Pharma, INC. | $52.43 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.48 | 2021 | |
| Allergan, INC. | $46.73 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.08 | 2019-2022 | |
| Pfizer INC. | $41.60 | 2019-2021 | |
| Mylan Specialty L.P. | $39.53 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $33.80 | 2022 | |
| Biogen, INC. | $31.47 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $25.45 | 2019-2020 | |
| Dermira, INC. | $24.64 | 2020 | |
| Genentech USA, INC. | $18.60 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $18.28 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.08 | 2022 | |
| Philips North America LLC | $14.34 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $14.31 | 2019 | |
| Amneal Pharmaceuticals LLC | $13.46 | 2020 | |
| Merck Sharp & Dohme LLC | $12.49 | 2021 | |
| Ironshore Pharmaceuticals INC. | $11.81 | 2021 | |
| Horizon Therapeutics Plc | $11.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.